Literature DB >> 19833157

The RNA-binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases.

Hiroshi Doi1, Shigeru Koyano, Yume Suzuki, Nobuyuki Nukina, Yoshiyuki Kuroiwa.   

Abstract

Neuronal intranuclear inclusions (NIIs) are the pathological hallmark of polyglutamine (polyQ) diseases. We previously found that the RNA-binding protein FUS/TLS is the major component of nuclear polyQ aggregates of a cellular model of Huntington disease. In this study, we revealed that FUS/TLS binds to NIIs in the human brains from patients with spinocerebellar ataxia type 1, 2, 3, and dentatorubral-pallidoluysian atrophy. Recent reports have revealed that mutations in FUS/TLS gene are responsible for familial amyotrophic lateral sclerosis 6 (ALS6). Our results indicated that changing FUS/TLS to an insoluble form may be a common process in polyQ diseases and ALS6. Copyright 2009 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833157     DOI: 10.1016/j.neures.2009.10.004

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  49 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

2.  FUS immunogold labeling TEM analysis of the neuronal cytoplasmic inclusions of neuronal intermediate filament inclusion disease: a frontotemporal lobar degeneration with FUS proteinopathy.

Authors:  Tristan Page; Michael A Gitcho; Sabrina Mosaheb; Deborah Carter; Sumi Chakraverty; Robert H Perry; Eileen H Bigio; Marla Gearing; Isidre Ferrer; Alison M Goate; Nigel J Cairns; Julian R Thorpe
Journal:  J Mol Neurosci       Date:  2011-05-21       Impact factor: 3.444

Review 3.  The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.

Authors:  Oliver D King; Aaron D Gitler; James Shorter
Journal:  Brain Res       Date:  2012-01-21       Impact factor: 3.252

Review 4.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 5.  Long non-coding RNAs in nervous system function and disease.

Authors:  Irfan A Qureshi; John S Mattick; Mark F Mehler
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

Review 6.  Prions, amyloids, and RNA: Pieces of a puzzle.

Authors:  Anton A Nizhnikov; Kirill S Antonets; Stanislav A Bondarev; Sergey G Inge-Vechtomov; Irina L Derkatch
Journal:  Prion       Date:  2016-05-03       Impact factor: 3.931

7.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

8.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

9.  FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.

Authors:  Manuela Neumann; Eva Bentmann; Dorothee Dormann; Ali Jawaid; Mariely DeJesus-Hernandez; Olaf Ansorge; Sigrun Roeber; Hans A Kretzschmar; David G Munoz; Hirofumi Kusaka; Osamu Yokota; Lee-Cyn Ang; Juan Bilbao; Rosa Rademakers; Christian Haass; Ian R A Mackenzie
Journal:  Brain       Date:  2011-08-19       Impact factor: 13.501

Review 10.  RNA-mediated toxicity in neurodegenerative disease.

Authors:  Veronique V Belzil; Tania F Gendron; Leonard Petrucelli
Journal:  Mol Cell Neurosci       Date:  2012-12-29       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.